Last reviewed · How we verify
Adjuvanted seasonal trivalent inactivated influenza vaccine
Adjuvanted seasonal trivalent inactivated influenza vaccine is a Biologic drug developed by PATH. It is currently in Phase 2 development. Also known as: Fluad.
At a glance
| Generic name | Adjuvanted seasonal trivalent inactivated influenza vaccine |
|---|---|
| Also known as | Fluad |
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) (PHASE3)
- Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 (PHASE2)
- A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity (NA)
- Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (PHASE4)
- Influenza Vaccination Among the Elderly Individuals
- Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases. (PHASE2)
- Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvanted seasonal trivalent inactivated influenza vaccine CI brief — competitive landscape report
- Adjuvanted seasonal trivalent inactivated influenza vaccine updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about Adjuvanted seasonal trivalent inactivated influenza vaccine
What is Adjuvanted seasonal trivalent inactivated influenza vaccine?
Adjuvanted seasonal trivalent inactivated influenza vaccine is a Biologic drug developed by PATH.
Who makes Adjuvanted seasonal trivalent inactivated influenza vaccine?
Adjuvanted seasonal trivalent inactivated influenza vaccine is developed by PATH (see full PATH pipeline at /company/path).
Is Adjuvanted seasonal trivalent inactivated influenza vaccine also known as anything else?
Adjuvanted seasonal trivalent inactivated influenza vaccine is also known as Fluad.
What development phase is Adjuvanted seasonal trivalent inactivated influenza vaccine in?
Adjuvanted seasonal trivalent inactivated influenza vaccine is in Phase 2.
Related
- Manufacturer: PATH — full pipeline
- Also known as: Fluad